Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
Hopefully good RNS rupans at 1430hrs :-)
"People often say 'don't invest more than you can comfortably afford to lose' in a company. If one is prepared to wait a while is AVCT a 'can't lose' company now?"
DG.....totally agree with the "can't lose" now comment :-), tell your girls they need to show a little more patience :-) All joking aside I hope everyone invested here reaps significant financial rewards and cancer sufferers reap the ultimate rewards.
The FUD merchants have been shot down today big time......wonder what angle they will use next.....comical :-)
Hoots Mon! there's a moose loose aboot this hoose
Totally agree Timster, as others have stated looks like Avacta are not far away now from commercial stages....fantastic :-)
AVA6000 Conclusions taken from presentation.
Dose Escalation
• AVA6000 has a modest and predictable safety profile across the dose range (80-200mg/m2)
• PK data for released doxorubicin highlights a positive profile
• Doxorubicin Exposure (AUC) & Maximal Concentrations (Cmax) substantially reduced across doses
• Doxorubicin concentrations are higher in tumour biopsies compared to plasma at 24 hrs timepoint
• Emerging PK profiles offer the opportunity to increase dosing duration & intensity of doxorubicin targeted to the
tumour
Confidence in Development Strategy for AVA6000 in 1st Line Soft Tissue Sarcoma (STS)
• Advanced, Metastatic STS tumours are known to be highly FAP positive
• Doxorubicin monotherapy is the only therapy indicated for first-line advanced, metastatic STS
• Large unmet clinical need in STS to improve patients outcomes in difficult to treat tumours
• AVA6000 preferentially targets the tumour environment using FAP specificity to activate doxorubicin
• AVA6000 can safely deliver larger doses of doxorubicin to tumour whilst sparing healthy tissues and organs.
"The data continue to show a very favourable safety profile for the tumour targeted chemotherapy and several patients in cohort 5 and earlier cohorts remain on treatment as their disease has not progressed"
Could the "Not Progressed" wording in the last RNS also cover words like (Regressed / Shrinkage) but at this early stage of the trial Avacta would never be permitted to use any other description besides "Not Progressed". I realize this is all meaningless at this stage, however, I was just wondering :-)
Hope you’re enjoying your holiday Wyn. BTW, I recently purchased a 3 piece (suite 🤣) and the waist coat was far too small, the jacket way too big and the baggy trousers way too short. I looked like a clown 🤡. I guess your wardrobe has a good selection of these (suites 🤣)
Couldn’t resist and BTW….. I do genuinely mean enjoy your vacation and keep up the banter 😊